Swiss National Bank
MLYS icon

Swiss National Bank’s Mineralys Therapeutics MLYS Stock Holding History

Swiss National Bank’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Buy
111,600
+21,500
+24% +$590K ﹤0.01% 1712
2026
Q1 		$2.44M Hold
90,100
– – ﹤0.01% 1750
2025
Q4 		$3.27M Buy
90,100
+1,600
+2% +$64.2K ﹤0.01% 1602
2025
Q3 		$3.36M Buy
88,500
+26,600
+43% +$575K ﹤0.01% 1564
2025
Q2 		$838K Buy
+61,900
New +$897K ﹤0.01% 2207

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swiss National Bank's MLYS Position: Q2 2026 in Review

Swiss National Bank increased its Mineralys Therapeutics (MLYS) stake by 24% in Q2 2026, buying an estimated $590K and bringing the position to 111,600 shares worth $3.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

Swiss National Bank first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.36M in Q3 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Swiss National Bank held 111,600 shares of Mineralys Therapeutics worth $3.01M as of Q2 2026.
  • Swiss National Bank bought 21,500 Mineralys Therapeutics shares in Q2 2026, an estimated $590K.
  • Mineralys Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1712 holding.
  • Swiss National Bank first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Swiss National Bank's Mineralys Therapeutics position peaked at $3.36M in Q3 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.